These results demonstrate that the functional properties of the NANOG/HDAC1 axis are conserved across multiple types of cancer cells and that HDAC1 is an appropriate target for controlling immune-refractory NANOGhi tumor cells. The gene discussed is NANOG; the disease is cancer.